GLP-1 receptor agonists market is anticipated to showcase a considerable CAGR during the forecast period. The increasing R&D and huge investment by the major market players for the development of new products along with the high prevalence of type 2 diabetic patients across the globe are the key factors responsible for the high growth of the GLP-1 receptor agonists market across the globe. GLP-1 receptor agonists are a category of antidiabetic agents that performs functioning of the glucagon-like peptide. GLP-1 is a natural incretin compound that influences the body functioning once they get released from the gut during digestion.
The combination of GLP-1 receptors, GLP-1 agonists, and endogenous GLP-1 is capable to reduce blood glucose levels to facilitate Type 2 diabetes patients to reach glycemic control. The proper intake of the GLP-1 receptor agonists increases the glucose-dependent secretion of insulin from functioning beta cells. Moreover, its intake decreases the glucagon release after meals, decrease hepatic glucose production, delayed gastric emptying, suppress the appetite and promotes beta-cell proliferation. According to the International Diabetic Federation (IDF) in 2019, nearly 463 million adults (20-79 years) were living with diabetes across the globe and this figure is anticipated to reach 700 million by 2045.
Diabetes is responsible for nearly $760 billion in health expenditure in 2019 that resembles 10% of total spending on adults for their health treatment. In 2019, 374 million people are observed to be at an increased risk of developing type 2 diabetes. The considerably high prevalence of this chronic disorder is creating the demand for the market growth of the GLP-1 receptor agonists. Bristol Mayer Squibb, Novo Nordisk A/S, Sanofi SA, Eli Lilly & Company, AstraZeneca PLC, and Merck & Co., Inc are the key players operating in the global GLP-receptor agonists market that are making hefty investments in the R&D of new drugs. Moreover, these players are actively adopting other growth strategies such as mergers & acquisitions, strategic agreements, partnerships, and collaborations in order to remain competitive in the global GLP-1 receptor agonists market.
To Request a Sample of our Report on GLP-1 Receptor Agonists Market: https://www.omrglobal.com/request-sample/glucagon-like-peptide-1-glp-1-receptor-agonists-market
GLP-1 Receptor Agonists Market Segmentation
By Drug Type
- Exenatide
- Liraglutide
- Lixisenatide
- Dulaglutide
A full report of GLP-1 Receptor agonists Market is available at: https://www.omrglobal.com/industry-reports/glucagon-like-peptide-1-glp-1-receptor-agonists-market
GLP-1 Receptor agonists Market– Segment by Region
North America
- United States
- Canada
Europe
- Germany
- United Kingdom
- France
- Spain
- Italy
- Rest of Europe
Asia-Pacific
- China
- Japan
- India
- Rest of Asia-Pacific
Rest of the World
- Middle East & Africa
- Latin America
Company Profiles
- AstraZeneca PLC
- Bristol Mayer Squibb, Co.
- Eli Lilly & Company
- Merck & Co., Inc.
- Novo Nordisk A/S
- Sanofi SA
Reasons to Buy From us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Contact Person: Mr. Anurag Tiwari
Email: anurag@omrglobal.com
Contact no: +91 780-304-0404
Company Name: Orion Market Research
